Physician profile
Daniel Bellingham
NPI 1205828969
$8,192.53
in general payments reported to CMS, 2019-2025
48 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $2,193 · 2021: $1,442 · 2022: $588 · 2023: $638 · 2024: $524 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,178.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,031.94 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $670.81 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $548.91 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $544.60 | 2019-2025 | |
| Abbvie INC. | $499.36 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.12 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $360.85 | 2019-2023 | |
| Glaxosmithkline, LLC. | $279.97 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $262.92 | 2019-2021 | |
| Allergan, INC. | $205.26 | 2020 | |
| Supernus Pharmaceuticals, INC. | $194.99 | 2019-2021 | |
| Amarin Pharma, INC. | $182.95 | 2019-2021 | |
| Dexcom, INC. | $173.42 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $167.08 | 2019-2020 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bellingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.